Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects With Classic Congenital Adrenal Hyperplasia

NCT04457336 is registered in ClinicalTrials.gov with Spruce Biosciences as lead sponsor.

NCT NCT04457336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04457336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects With Classic Congenital Adrenal Hyperplasia
Lead sponsor
Spruce Biosciences
Phase
Phase 2
Overall status
Terminated
Start date
August 26, 2020
Completion date
May 23, 2024
Enrollment
96 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

congenital adrenal hyperplasia